Midazolam Accord (Midazolam)

Midazolam enhances the activity of the neurotransmitter gamma‑aminobutyric acid (GABA) by binding to a specific site on the GABA‑A receptor. This positive allosteric modulation increases chloride ion influx, leading to neuronal hyperpolarization and reduced excitability, which produces sedation, anxiolysis, muscle relaxation, and seizure control.

The dose of Midazolam Accord is individualized by the prescribing clinician based on the intended indication, patient age, weight, clinical condition, and route of administration. Dosing regimens are established in clinical guidelines and must be tailored to each patient’s response and safety considerations.

Midazolam is classified as pregnancy category unknown, and limited data exist on its safety for the fetus or nursing infant. Caution is advised, and the drug should only be used during pregnancy or lactation when the potential benefit justifies any potential risk to the child.

To order Midazolam Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Midazolam offers a rapid onset, short duration of action, and a favorable safety profile compared with longer‑acting benzodiazepines such as diazepam. Unlike propofol, it provides amnestic properties and is less likely to cause pain on injection, making it a preferred choice for brief procedures and seizure emergencies.

Midazolam Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Inspect the solution for particulate matter or discoloration before use and discard if any abnormalities are observed.

Midazolam can be given by intramuscular, intravenous, or rectal routes, depending on the clinical situation. Intravenous administration provides the fastest onset, while intramuscular injection is useful when IV access is unavailable. Rectal administration is an alternative for seizure control in emergency settings.

The most serious risks include severe respiratory depression, especially when combined with other CNS depressants, paradoxical reactions such as agitation or aggression, profound hypotension, and rare anaphylactic reactions. Continuous monitoring of respiratory and cardiovascular status is essential during and after administration.

Midazolam should be avoided in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are pregnant or breastfeeding unless the benefit outweighs the risk. Caution is also required in individuals with significant hepatic impairment or a history of substance dependence.